Biopharmaceutical company Versartis, Inc. has selected Comprehend Systems to help facilitate compilation of real-time study information and subject data. Comprehend Clinical, a cloud-based platform that allows sponsors to access and analyze data from any clinical IT system.

Versartis is developing VRS-317, a novel, long-acting form of recombinant human growth hormone for the treatment of growth hormone deficiency (GHD). VRS-317 is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance and therefore treatment outcomes. The company is currently completing a Phase II clinical trial of VRS-317 in children with GHD.

Versartis selected Comprehend for its ability to provide real-time access to the data in its studies and to simplify what had been a time-consuming process managing multiple data sources. With Comprehend, the company’s clinical operations team has a complete view of every study and access to study information real-time via intuitive dashboards. And once created, those dashboards can be re-used and updated automatically.

News

Biopharmaceutical company Versartis, Inc. has selected Comprehend Systems